Preventing Retinal Blindness

• AMD involves inflammation and activation of the complement system.
• Over activity of the complement system can lead to increased production of pro-inflammatory cytokines such as VEGF in the retina.
• Effectiveness of repeat injections of anti-VEGF therapies in AMD and DME reduces over time (i.e. refractility) and can promote MA.
• Eye Co’s treatments are designed to reduce inflammation and prevent Macular Atrophy (MA) resulting from extended anti-VEGF treatment in Age-Related Macular Degeneration (AMD) and Diabetic Macular Oedema (DME).